WAS
TEVA icon

WESPAC Advisors SoCal’s Teva Pharmaceuticals TEVA Stock Holding History

WESPAC Advisors SoCal’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-140
Closed -$4K – 275
2017
Q2 		$4K Hold
140
– – ﹤0.01% 216
2017
Q1 		$4.49K Buy
+140
New +$4.78K ﹤0.01% 215
2016
Q4 		– Sell
-3,550
Closed -$163K – 286
2016
Q3 		$163K Hold
3,550
– – 0.11% 84
2016
Q2 		$178K Buy
3,550
+50
+1% +$2.66K 0.12% 80
2016
Q1 		$187K Buy
3,500
+125
+4% +$7.33K 0.14% 75
2015
Q4 		$221K Buy
+3,375
New +$209K 0.15% 77

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

WESPAC Advisors SoCal's TEVA Position: Q3 2017 in Review

WESPAC Advisors SoCal sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 140 shares — an estimated $4K sold.

WESPAC Advisors SoCal first reported a position in TEVA in Q4 2015 and held it in 6 quarters. The position peaked at $221K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • WESPAC Advisors SoCal reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 140 Teva Pharmaceuticals shares in Q3 2017, an estimated $4K.
  • WESPAC Advisors SoCal first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • WESPAC Advisors SoCal's Teva Pharmaceuticals position peaked at $221K in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on WESPAC Advisors SoCal's 13F filing for Q3 2017, filed 3 Nov 2017.